Wall Street is positive on Invo Bioscience Inc (INVO). On average, analysts give the stock a Buy rating. The average price target is $4.5, which means analysts expect the stock to rise by 278.15% over the next twelve months. That average ranking earns the stock an Analyst Rating of 30, which is better than 30% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating INVO a Buy today. Find out what this means to you and get the rest of the rankings on INVO!